While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development ...

With a $50 million initial investment from Flagship, Terrana will use RNA from benign plant viruses as a chassis to carry ...

The innate immune system is the body's first line of defense against pathogens and foreign substances. An essential component ...

A University of California, Riverside-led team has made an advance in the basic understanding of Plasmodium falciparum, the ...

Global Antisense and RNAi therapeutics Market is valued approximately at USD 3.69 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.72% over the forecast period ...

BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Terrana Biosciences will develop crop protection inputs using RNA technology, which was used by Flagship portfolio company Moderna to develop its covid-19 vaccine.

By uncovering RNA’s previously unknown function to repair DNA damage, our findings show how RNA may directly contribute to the stability and evolution of the genome. It’s not merely a passive ...

STUTTGART, Germany I June 27, 2025 I La Merie Publishing announced the release of its newest technology market report about gene therapy technologies for in vivo expression of antibodies. The report ...